Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs

The Indianapolis-based firm reported adjusted earnings of $7.02 per share on revenue that soared 54% year- over-year to $17.60 billion for the third quarter. Analysts surveyed by Visible Alpha had expected $5.91 and $16.06 billion, respectively. Mounjaro sales more than doubled to $6.52 billion, topping projections of $5.41 billion. Sales of Zepbound nearly tripled to $3.59 billion, while analysts had estimated $3.37 billion. Why This News Matters Eli Lilly, the maker of weight-loss drug Zepbound, lifted it ...